|
A-PBITMO
A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023, and also subsequently identified in Russia. It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs. See also * A-PONASA * AB-001 * AM-1248 * APINACA * FUBIMINA FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole structural analog, analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in J ... * PF-03550096 References Cannabinoids Designer drugs Adamantanes Thioureas {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
A-PONASA
A-PONASA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug. It is closely related to the previously reported compound CB-13 but with the naphthalene head group replaced with adamantyl, and an unusual sulfonamide linker group. See also * A-PBITMO * AZD-1940 * 2F-QMPSB 2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug. Its identification was first reported by a forensic laboratory in Italy in January 2019, and it wa ... References Cannabinoids Designer drugs Adamantanes Sulfonamides Naphthol ethers {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-001
AB-001 (1-pentyl-3-(1-adamantoyl)indole) is a designer drug that was found as an ingredient in synthetic cannabis smoking blends in Ireland in 2010 and Hungary and Germany in 2011. It is unclear who AB-001 was originally developed by, but it is structurally related to compounds such as AM-1248 and its corresponding 1-(tetrahydropyran-4-ylmethyl) analogue, which are known to be potent cannabinoid agonists with moderate to a high selectivity for CB2 over CB1. The first published synthesis and pharmacological evaluation of AB-001 revealed that it acts as a full agonist at CB1 (EC50 = 35 nM) and CB2 receptors (EC50 = 48 nM). However, AB-001 was found to possess only weak cannabimimetic effects in rats at doses up to 30 mg/kg, making it less potent than the carboxamide analogue APICA, which possesses potent cannabimimetic activity at doses of 3 mg/kg. See also * A-834,735 * A-PBITMO * AB-005 AB-005 or 1-methylpiperidin-2-yl)methyl.html" ;"title="-[(1-methylpiperid ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AM-1248
AM-1248 is a drug that acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2, but with some dispute between sources over its exact potency and selectivity. Replacing the 3-(1-naphthoyl) group found in many indole derived cannabinoid ligands, with an adamant oyl group, generally confers significant CB2 selectivity, but reasonable CB1 affinity and selectivity is retained when an N-methylpiperidin-2-ylmethyl substitution is used at the indole 1-position. The related compound 1-pentyl-3-(1-adamantoyl)indole was identified as having been sold as a cannabinoid Cannabinoids () are several structural classes of compounds found primarily in the ''Cannabis'' plant or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoact ... designer drug in Hungary in 2011, along with another synthetic cannabinoid AM-679. Legality Sweden's public health agency suggested to classify ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PF-03550096
PF-03550096 is a drug that acts as a potent agonist for the CB2 cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome, but has only progressed to animal studies. See also * A-PBITMO * AB-FUBINACA AB-FUBINACA ( AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. I ... * AB-PINACA References Cannabinoids {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. These novel Psychoactive drug, psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis) or synthetic Cannabinoid, endocannabinoids from which they are distinct in many aspects. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the United States and United Kingdom since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names such as K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid leg ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these designer drugs were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human tr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
APINACA
APINACA (AKB48, ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB1 with an EC50 of 142 nM and Ki of 3.24 nM (compared to the Ki of Δ9-THC at 28.35 nM and JWH-018 at 9.62 nM), while at CB2 it acts as a partial agonist with an EC50 of 141 nM and Ki of 1.68 nM (compared to the Ki of Δ9-THC at 37.82 nM and JWH-018 at 8.55 nM). Its pharmacological characterization has also been reported in a discontinued patent application. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with a related compound APICA. Structurally, it closely resembles cannabinoid compounds from a University of Connecticut patent, but with a simple pentyl chain on the indazole 1-position, and APINACA falls within the claims of this patent de ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUBIMINA
FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole structural analog, analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM. FUBIMINA acts as a reasonably potent agonist for the CB2 receptor, CB2 receptor (dissociation constant, ''K''i = 23.45 nM), with 12x selectivity over CB1 receptor, CB1 (''K''i = 296.1 nM), and does not fully substitute for Tetrahydrocannabinol, Δ9-THC in rat discrimination studies. Related benzimidazole derivatives have been reported to be highly selective agonists for the Cannabinoid receptor type 2, CB2 receptor. See also * AM-694 * AM-1235 * AM-2232 * AM-2233 * BIM-018 * JWH-018 * List of AM cannabinoids * List of JWH cannabinoids * THJ-2201 References Benzimidazoles Cannabinoids Designer drugs Organofluorides 1-Naphthyl compounds {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cannabinoids
Cannabinoids () are several structural classes of compounds found primarily in the ''Cannabis'' plant or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoactive compound in cannabis. Cannabidiol (CBD) is also a major constituent of temperate cannabis plants and a minor constituent in tropical varieties. At least 100 distinct phytocannabinoids have been isolated from cannabis, although only four (i.e., THCA, CBDA, CBCA and their common precursor CBGA) have been demonstrated to have a biogenetic origin. It was reported in 2020 that phytocannabinoids can be found in other plants such as rhododendron, licorice and liverwort, and earlier in Echinacea. Phytocannabinoids are multi-ring phenolic compounds structurally related to THC, but endocannabinoids are fatty acid derivatives. Nonclassical synthetic cannabinoids (cannabimimetics) include aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these designer drugs were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human tr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
